332 related articles for article (PubMed ID: 3135160)
1. Antibiotic therapy in cystic fibrosis. Evaluation of efficacy.
Levy J
Chest; 1988 Aug; 94(2 Suppl):150S-156S. PubMed ID: 3135160
[TBL] [Abstract][Full Text] [Related]
2. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Smith S; Waters V; Jahnke N; Ratjen F
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD009528. PubMed ID: 32520436
[TBL] [Abstract][Full Text] [Related]
3. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2015 Mar; (3):CD009528. PubMed ID: 25741986
[TBL] [Abstract][Full Text] [Related]
4. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2012 Nov; 11():CD009528. PubMed ID: 23152277
[TBL] [Abstract][Full Text] [Related]
5. Multiresistant pulmonary infection in cystic fibrosis--prevention is better than cure.
Smyth A
Lancet; 2005 Aug 6-12; 366(9484):433-5. PubMed ID: 16084235
[No Abstract] [Full Text] [Related]
6. The approach to Pseudomonas aeruginosa in cystic fibrosis.
Bendiak GN; Ratjen F
Semin Respir Crit Care Med; 2009 Oct; 30(5):587-95. PubMed ID: 19760546
[TBL] [Abstract][Full Text] [Related]
7. Changes in strategies for optimal antibacterial therapy in cystic fibrosis.
Ratjen F
Int J Antimicrob Agents; 2001 Feb; 17(2):93-6. PubMed ID: 11165111
[TBL] [Abstract][Full Text] [Related]
8. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Greally P; Whitaker P; Peckham D
Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602
[TBL] [Abstract][Full Text] [Related]
9. Antibiotic perturbation of mixed-strain Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Tai AS; Sherrard LJ; Kidd TJ; Ramsay KA; Buckley C; Syrmis M; Grimwood K; Bell SC; Whiley DM
BMC Pulm Med; 2017 Nov; 17(1):138. PubMed ID: 29096618
[TBL] [Abstract][Full Text] [Related]
10. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients.
Taccetti G; Campana S; Festini F; Mascherini M; Döring G
Eur Respir J; 2005 Sep; 26(3):458-61. PubMed ID: 16135728
[TBL] [Abstract][Full Text] [Related]
11. Levofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis.
Stockmann C; Hillyard B; Ampofo K; Spigarelli MG; Sherwin CM
Expert Rev Respir Med; 2015 Feb; 9(1):13-22. PubMed ID: 25417708
[TBL] [Abstract][Full Text] [Related]
12. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Parkins MD; Elborn JS
Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients.
Ciofu O; Tolker-Nielsen T; Jensen PØ; Wang H; Høiby N
Adv Drug Deliv Rev; 2015 May; 85():7-23. PubMed ID: 25477303
[TBL] [Abstract][Full Text] [Related]
14. Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa.
Klepac-Ceraj V; Lemon KP; Martin TR; Allgaier M; Kembel SW; Knapp AA; Lory S; Brodie EL; Lynch SV; Bohannan BJ; Green JL; Maurer BA; Kolter R
Environ Microbiol; 2010 May; 12(5):1293-303. PubMed ID: 20192960
[TBL] [Abstract][Full Text] [Related]
15. [Current microbiological data on lower respiratory tract infection in cystic fibrosis. Part I: Isolated microorganisms and their clinical significance].
Coman G; Petraru E; Dahorea C; Anton DT
Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):580-7. PubMed ID: 23077957
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial therapy against Staphylococcus aureus, Pseudomonas aeruginosa, and Pseudomonas cepacia.
Geddes DM
Chest; 1988 Aug; 94(2 Suppl):140S-145S. PubMed ID: 3293940
[TBL] [Abstract][Full Text] [Related]
17. A more objective approach to the evaluation of antimicrobial therapy in cystic fibrosis.
Valletta EA; Rigo A; Bonazzi L; Zanolla L; Mastella G
Acta Univ Carol Med (Praha); 1990; 36(1-4):44-5. PubMed ID: 2130717
[TBL] [Abstract][Full Text] [Related]
18. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
Al-Aloul M; Nazareth D; Walshaw M
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
[TBL] [Abstract][Full Text] [Related]
19. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection.
Milla CE; Chmiel JF; Accurso FJ; VanDevanter DR; Konstan MW; Yarranton G; Geller DE;
Pediatr Pulmonol; 2014 Jul; 49(7):650-8. PubMed ID: 24019259
[TBL] [Abstract][Full Text] [Related]
20. Rational parameters for antibiotic therapy in patients with cystic fibrosis.
Govan JR; Doherty C; Glass S
Infection; 1987; 15(4):300-7. PubMed ID: 3117704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
